TuHURA Biosciences, Inc. (HURA)
| Market Cap | 159.21M -4.1% |
| Revenue (ttm) | n/a |
| Net Income | -30.93M |
| EPS | -0.59 |
| Shares Out | 63.68M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 642,714 |
| Open | 2.330 |
| Previous Close | 2.340 |
| Day's Range | 2.330 - 2.585 |
| 52-Week Range | 0.410 - 3.900 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 8.40 (+236.0%) |
| Earnings Date | May 15, 2026 |
About HURA
TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company’s lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. It is also preparing to initiate a single randomized placebo-controlled which is in Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda; and Delta receptor technology to develop tumor microenvironment modulators in the form... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for HURA stock is "Buy." The 12-month stock price target is $8.4, which is an increase of 236.00% from the latest price.
News
TuHURA Biosciences Reports First Quarter 2026 Financial Results and Provides a Corporate Update
TAMPA, Fla., May 15, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ: HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to...
TuHURA Biosciences to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference
TAMPA, Fla., May 12, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to ...
TuHURA Biosciences initiated with an Outperform at Citizens
Citizens initiated coverage of TuHURA Biosciences (HURA) with an Outperform rating and $9 price target TuHURA is a clinical-stage immuno-oncology company focused on novel mechanisms in cancer, the ana...
TuHURA Biosciences Announces $50 Million Credit Facility and Royalty Transaction Extending Anticipated Cash Runway into 2028
Credit facility anticipated to fund development of pipeline, including IFx-2.0 through Phase 3 results and TBS-2025 to key efficacy measurement milestones TAMPA, Fla., April 22, 2026 /PRNewswire/ -- T...
TuHURA Biosciences initiated with a Buy at Rodman & Renshaw
Rodman & Renshaw initiated coverage of TuHURA Biosciences (HURA) with a Buy rating and $7 price target The firm’s target is based on its estimate of the probability-adjusted sum-of-the-parts valuation...
TuHURA Biosciences Appoints Amanda Garofalo, MSHS, as Senior Vice President of Clinical Operations
Mrs. Garofalo brings over 20 years of experience in Phase I-IV drug and biologic development TAMPA, Fla., April 7, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company...
TuHURA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update
TAMPA, Fla., April 1, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to...
Craig Tendler, M.D., JNJ's Former Global Head of Oncology Clinical Development, to Lead TuHURA Bioscience's VISTA Program in AML and other Blood Related Cancers
Distinguished physician with a career spanning over 29 years in drug development and medical affairs highlighted by blockbuster successes in hematology and oncology Coordinated and achieved more than ...
TuHURA Biosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement
TAMPA, Fla., Feb. 27, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to...
TuHURA Biosciences Announces Participation in Upcoming Investor Conferences
TAMPA, Fla., Feb. 24, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to...
TuHURA Biosciences files INDA for TBS-2025 in blood-related cancers
TuHURA Biosciences (HURA) has filed an Investigational New Drug Application, or INDA, with the FDA’s Division of Hematologic Malignancies 1 for the study of TBS-2025, a novel VISTA inhibiting antibody...
TuHURA Files Investigational New Drug Application for TBS-2025 in the Treatment of Blood-Related Cancers
TBS-2025 to be investigated in combination with a menin inhibitor in mutNPM1 r/r AML TAMPA, Fla., Feb. 17, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Ph...
TuHURA Biosciences to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
TAMPA, Fla., Feb. 12, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to...
TuHURA Biosciences says FDA grants Orphan Drug Designation to IFx-2.0
TuHURA Biosciences (HURA) announced that the U.S FDA Office of Orphan Products Development has granted Orphan Drug Designation to IFx-2.0 for the treatment of stage IIB to stage IV cutaneous…
TuHURA Biosciences received FDA Orphan Drug Designation for IFx-2.0 for the Treatment of Stage IIB to Stage IV Cutaneous Melanoma
TAMPA, Fla., Feb. 2, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to ...
TuHURA Biosciences price target lowered to $10 from $12 at H.C. Wainwright
H.C. Wainwright analyst Robert Burns lowered the firm’s price target on TuHURA Biosciences (HURA) to $10 from $12 and keeps a Buy rating on the shares. The firm says the…
TuHURA Biosciences announces release of Kintara’s CVR
TuHURA Biosciences (HURA) announced that Kintara’s REM-001 clinical trial of ten metastatic cutaneous breast cancer patients met its primary endpoint demonstrating safety with signs of clinical effica...
TuHURA Biosciences Announces its Release of Kintara's Contingent Value Right (CVR) as Kintara's REM-001 Meets Primary Safety Endpoint Achieving Contractual Milestone
Milestone Triggers Release of Shares to Kintara Contingent Value Right (CVR) Holders TAMPA, Fla. , Dec. 15, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a P...
TuHURA Biosciences provides updates across portfolio
TuHURA Biosciences (HURA) provided updates across the company’s portfolio of assets, including a summary from its mini symposium held on December 5, 2025 focused on targeting VISTA in AML, the…
TuHURA Biosciences Provides Corporate Update Following Recent Financing
Company's lead Phase 3 program of IFx-2.0 as adjunctive therapy with Keytruda® (pembrolizumab) as a first-line therapy for advanced and metastatic Merkel cell carcinoma (MCC), conducted under a Specia...
TuHURA Biosciences announces $15.6M registered direct offering
TuHURA Biosciences (HURA) announced that it has entered into a definitive agreement for the purchase of an aggregate of 9,462,423 shares of its common stock, Series A warrants to purchase…
TuHURA Biosciences, Inc. Announces $15.6 Million Registered Direct Offering
TAMPA, Fla. , Dec. 9, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to...
TuHURA Biosciences presents research on potential role of DOR at ASH
TuHURA Biosciences (HURA) announced that its research on the potential role of the Delta Opioid Receptor in controlling the immunosuppressive capabilities of MDSCs was presented in an oral presentatio...
TuHURA Biosciences Presents Data Demonstrating the Delta Opioid Receptor (DOR) as a New Target in Overcoming Acquired Resistance to Immune Checkpoint Inhibitors at the 57th ASH Annual Meeting and Exposition
Oral Presentation highlighted new scientific evidence that DOR is expressed on tumor-associated Myeloid-Derived Suppressor Cells (MDSCs), and its inhibition decreases immune suppressing capabilities o...
TuHURA Biosciences price target lowered to $8 from $15 at Maxim
Maxim lowered the firm’s price target on TuHURA Biosciences (HURA) to $8 from $15 and keeps a Buy rating on the shares.